Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy (BIBC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2012 by Xijing Hospital
Sponsor:
Collaborator:
Roche Pharma AG
Information provided by (Responsible Party):
LiNanlin,Ph.D, Chief Physician,Clinical Professor, Xijing Hospital
ClinicalTrials.gov Identifier:
NCT01652560
First received: July 21, 2012
Last updated: July 25, 2012
Last verified: July 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2014
  Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)